Eclipse Treatment Planning System
FDA Clearance Information
The Eclipse Treatment Planning System was cleared by the FDA through the 510(k) pathway on July 5, 2017. It is manufactured by Varian Medical Systems and classified as a Class 2 device under product code MUJ.
What It Is
FDA-Cleared Indications
- Used to create treatment plans for radiation therapy.
- Calculates and evaluates dose distributions for photon and electron radiation beams.
- Supports treatment planning intended to deliver radiation to target tissues while limiting dose to surrounding normal tissues.
Clinical Applications
- Planning external-beam photon radiation therapy.
- Planning electron beam radiation therapy.
- Calculating radiation dose distributions in target tissues and organs at risk.
- Optimizing treatment plans for complex radiation therapy treatments.
- Planning treatments involving heterogeneous tissues or regions affected by metal-related imaging artifacts, when supported by the applicable system configuration and validation.
Evidence Summary
Reported Outcomes
Safety Profile
Evidence Limitations
Practical Considerations
- This is software, not an implanted or patient-contact device; it does not have physical size options.
- The system must be used with compatible treatment-planning, imaging, treatment-delivery and quality-assurance workflows.
- Dose calculations require appropriate patient imaging, tissue-density information, beam data and clinical validation.
- Metal implants and imaging artifacts can affect contouring and dose calculation; additional review and quality assurance may be required.
- It is not an MRI-safe device in the usual implantable-device sense. MRI images may be imported for planning when the scanner, imaging workflow and software configuration are compatible and validated.
Frequently Asked Questions
What are the clinical indications for Eclipse Treatment Planning System?
The Eclipse system is indicated for use in planning radiation therapy treatments, particularly for calculating and optimizing dose distributions in cancer patients.
What outcomes have been reported in clinical studies?
Studies report accurate dose calculations and effective management of dosimetric uncertainties, with favorable comparisons to Monte Carlo simulations.
What complications have been reported?
Safety data indicates complications with dose calculation errors near metal artefacts, affecting treatment accuracy.